Medical/Pharmaceuticals

Lunit Gets FDA Nod for AI-based Chest X-ray Triage Solution, Developed for Sorting of Emergency Cases

- First FDA 510(k) clearance from its AI software product lineup for radiology, specialized in triaging emergent cases found in chest x-ray - Company to accelerate business in the US market, leveraging partnerships with Philips, FujiFilm - Product to be introduced during RSNA 2021 booth #4545 S...

2021-11-15 23:33 2351

Nanoform signs GMP agreement and achieves near-term business target

HELSINKI, Nov. 15, 2021 /PRNewswire/ -- Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling ...

2021-11-15 23:17 2258

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved

BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...

2021-11-15 22:47 3418

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company inSouth Korea, today...

2021-11-15 22:39 4566

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...

2021-11-15 20:00 4449

Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing

SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....

2021-11-15 19:00 2335

Vazyme goes public on Shanghai Stock Exchange today

NANJING, China, Nov. 15, 2021 /PRNewswire/ -- On November 15, 2021, Nanjing Vazyme Biotech Co., Ltd. (Vazyme) went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688105. Vazyme goes public on Shanghai Stock Exchan...

2021-11-15 16:28 5104

Labcorp Opens New Integrated Laboratory, Strengthens Bioanalytical Services In Asia-Pacific

SINGAPORE, Nov. 15, 2021 /PRNewswire/ -- Labcorp   (NYSE: LH), a leading global life sciences company, today announced the expansion of its global offerings and its footprint in theAsia-Pacific (APAC) region with the opening of a new, integrated bioanalytical laboratory in...

2021-11-15 16:00 4224

Qiming's Portfolio Company Aohua Endoscopy Lands on STAR Market

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Aohua Endoscopy (SHSE: 688212), a leading medical endoscope manufacturer, today landed on the STAR Market. The issue price isCNY 22.5 per share. The stock opened atCNY 33 per share, representing a market cap of CNY...

2021-11-15 15:06 3840

Wision A.I. Achieves CE-MDR Mark Approval for AI-assisted Diagnostic Software Medical Device Supporting Colonoscopy

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Wision A.I. Ltd, a startup in the field of artificial intelligence assisted diagnostics for gastrointestinal endoscopy, today announced it received the European CE Mark approval for EndoScreener, its AI-assisted polyp detection software during colonoscopy. ...

2021-11-15 08:30 2518

Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...

2021-11-15 08:30 3523

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver toxicity risk, computational analysis adds support to dosing strategy -ATG-017, an ERK1/2 inhibitor, in vivo combination supports c...

2021-11-15 08:25 3809

Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-15 08:00 3724

Ascensia Diabetes Care Announce Winner of This is Diabetes Art and Photo Competition

BASEL, Switzerland, Nov. 14, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, makers of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributors of the Eversense® continuous glucose monitoring (CGM) system, has announced the winner of its This is Diabe...

2021-11-14 15:00 3188

Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...

2021-11-13 02:56 5371

Global Accelerated Ventures, ACTUAL, and Bioassets Partner to Work With Enterprises to Make Total Decarbonization Possible

HIGH QUALITY, CERTIFIED CREDITS COMPLEMENT MEANINGFUL EMISSIONS REDUCTIONS FOR ENTERPRISES TO MEET THEIR NET-ZERO MANDATES GLASGOW, Scotland, Nov. 12, 2021 /PRNewswire/ -- Global Accelerated Ventures (GAV) and ACTUAL are partnering with Bioassets, to integrate high quality, provenanced carbon cr...

2021-11-12 23:20 6997

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Nov. 12, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.

2021-11-12 09:11 2897

Hetero and Shenzhen Beimei Pharmaceuticals launch antiviral drug Oselavir® in China

Oseltamivir phosphate is used in the treatment of acute uncomplicated influenza infection in adults, adolescents and children BEIJING, Nov. 12, 2021 /PRNewswire/ -- Hetero, a globally renowned vertically integrated pharmaceutical organization and Shenzhen Beimei Pharmaceuticals jointly announced...

2021-11-12 09:00 4205

Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03

* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...

2021-11-12 07:55 4277

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics

SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry andin-vitro ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small mo...

2021-11-11 21:33 3431
1 ... 358359360361362363364 ... 386

Week's Top Stories